Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
Abstract Background p-Boronophenylalanine (10BPA) is a powerful 10B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of 10BPA must be administered over a few hours. Here, we report BNCT efficacy after rapid, ultralow-dose administration of either tumor...
Main Authors: | Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh-Yoneyama, Taku Yoshiya, Tsuyoshi Uemura, Takehiro Ishizu, Minoru Suzuki, Shingo Hachinohe, Shintaro Ishiyama, Motohiro Nonaka, Michiko N. Fukuda, Chikara Ohyama |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-020-07760-x |
Similar Items
-
Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
by: Tohru Yoneyama, et al.
Published: (2021-01-01) -
Renal metastasis of ovarian granulosa cell tumor
by: Kyo Togashi, et al.
Published: (2022-05-01) -
Apoptosis, annexin A5 and anti-annexin A5 antibodies in the antiphospholipid syndrome
by: Bećarević Mirjana, et al.
Published: (2013-01-01) -
Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries
by: Sakae Konishi, et al.
Published: (2021-11-01) -
Plasma and Peritoneal Fluid Annexin A2 Levels in Patients with Endometriosis
by: Zygarowicz M, et al.
Published: (2023-12-01)